Abstract CT108: HELOISE: phase IIIB randomized multicenter study comparing two trastuzumab (H) dose regimens combined with chemotherapy (CT) as first-line (1L) therapy in patients (pts) with HER2-positive metastatic gastric/gastroesophageal junction adenocarcinoma (mGC/GEJC)
Year: 2016
Type: conference-abstract
Source: Cancer Research
Institutions: Cornell University, Weill Cornell Medicine, Sun Yat-sen University, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Seoul National University Hospital, Hospital Sírio-Libanês, Shanghai Medical College of Fudan University, Fudan University, Zhongshan Hospital, F. Hoffmann-La Roche AG, Roche (China), Annexon Biosciences (United States), Instacart (United States), Universitat Autònoma de Barcelona, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2497732665